# Progress Note 03 — Focused Visit (Follow-up)

> **SYNTHETIC RECORD, NOT A REAL MEDICAL RECORD**

- Patient: Alan Turing (real historical name used in a fictional teaching record)
- Synthetic MRN: HR-ML007-SYN-TD
- Date: 1953-06-09
- Fictional facility: St. Posthumous Health Center
- Fictional author: Rupert Hallam, MD
- Calendar frame: true historical dates (modern content is anachronistic)

> True-date frame: synthetic events are moved into the patient's historical lifetime. Codes, instruments, and treatments remain modern and are anachronistic.

- Visit type: Focused Visit (Follow-up)

## Chief complaint

Eight-week review of hormone recovery and depression treatment. **S**

## History of present illness

Mr. Turing returns eight weeks after his first visit, about eleven weeks after the last estrogen injection. The breast tenderness is less and he no longer notices it when running. Morning erections returned three weeks ago and his libido is coming back. He has had seven psychotherapy sessions and runs about 25 km a week. His mood is somewhat better, but he still feels flat most days, has little pleasure outside work, and wakes early. He has had no suicidal thoughts. After the last visit he asked to think about medicine; today, after a discussion of sertraline, mirtazapine, and bupropion and their effects on sexual function, weight, sleep, and blood pressure, he chose bupropion. He has no history of seizures, head injury, or an eating disorder and drinks little alcohol. **S**

| Element | Detail |
|---|---|
| Breasts | Less tender; no discharge |
| Sexual function | Morning erections back for three weeks; libido returning |
| Psychotherapy | Seven sessions |
| Running | About 25 km a week |
| Safety | No suicidal thoughts |
| PHQ-9 | 12, down from 15 |

## Review of systems

| System | Result | Finding |
|---|---|---|
| Breast | Positive | Mild tenderness on pressure only; no discharge |
| Genitourinary | Negative | Erections returning; no testicular symptoms |
| Neurological | Negative | No seizures, fainting, or head injury ever |
| Psychiatric | Positive | Flat mood and early waking; no suicidal thoughts, elevated mood, or racing thoughts |

4 systems reviewed. **S**

## Current medications

- Cholecalciferol 1,000 units (25 mcg) oral tablet, one tablet by mouth daily **S**
- Bupropion extended-release 150 mg oral tablet, one tablet by mouth each morning **S**

## Allergies

- No known allergy **S**

## Objective

BP 118/74 mmHg; pulse 58 bpm; respirations 14/min; temperature 36.6 °C; oxygen saturation 99% on room air; weight 70.1 kg; BMI 22.1 kg/m². All vital signs are synthetic.

PHQ-9: 12; GAD-7: 6; Total testosterone: 238 ng/dL (low); Estradiol: 26 pg/mL; LH: 2.4 m[IU]/mL; FSH: 3.1 m[IU]/mL; Prolactin: 12.4 ng/mL; Hemoglobin: 13.6 g/dL. All results are synthetic.

## Change since baseline

- PHQ-9: 15 at baseline, 12 at this visit **S**
- GAD-7: 8 at baseline, 6 at this visit **S**
- Total testosterone: 112 ng/dL (low) at baseline, 238 ng/dL (low) at this visit **S**
- Estradiol: 148 pg/mL (high) at baseline, 26 pg/mL at this visit **S**
- LH: 0.3 m[IU]/mL (low) at baseline, 2.4 m[IU]/mL at this visit **S**
- FSH: 0.4 m[IU]/mL (low) at baseline, 3.1 m[IU]/mL at this visit **S**
- Prolactin: 21.6 ng/mL (high) at baseline, 12.4 ng/mL at this visit **S**
- Hemoglobin: 13 g/dL (low) at baseline, 13.6 g/dL at this visit **S**

## Physical examination

| System | Finding |
|---|---|
| General | Lean; more animated than at intake |
| Breast | Examined with his agreement: glandular tissue about 3 cm behind each nipple, softer and only mildly tender; no discrete mass, skin change, discharge, or nodes |
| Mental status | Alert; mood "better, but grey"; affect mildly constricted and reactive; thought process linear; no suicidal ideation; insight and judgment good |

All examination findings are synthetic. **S**

## Assessment and plan

1. **Drug-induced hypogonadotropic hypogonadism, recovering** (E23.1). LH 2.4 and FSH 3.1 mIU/mL are back in range and testosterone has risen from 112 to 238 ng/dL, still low. Estradiol and prolactin are normal. Hemoglobin has normalized. **S**
   - Continue watchful recovery without testosterone therapy.
   - Testosterone, LH, FSH, and hemoglobin in eight weeks.
2. **Bilateral gynecomastia, improving** (N62). Smaller and less tender now that estradiol is normal. **S**
   - Continue watchful waiting.
3. **Major depressive disorder, single episode, with partial response at eight weeks** (F32.1). PHQ-9 12, down 20 percent from 15 after eight weeks of psychotherapy alone: a partial response. He chose to add an antidepressant. Bupropion suits his wish to avoid sexual side effects and weight change; he has no seizure risk factors. No past mania or hypomania. Suicide risk remains low. **S**
   - Start bupropion XL 150 mg each morning; nurse telephone check in two weeks for sleep, anxiety, blood pressure, and safety.
   - Continue weekly psychotherapy.
   - Collaborative safety plan reviewed and unchanged; 988 Suicide & Crisis Lifeline and the clinic number confirmed.

## Protocol monitoring

Items the monitoring protocol calls for at this visit. **S**

| Domain | Measure | Interval | Status | Detail |
|---|---|---|---|---|
| Examination | Breast examination for size, tenderness, and any discrete mass | Every visit until the gynecomastia settles | Completed today | Glandular tissue about 3 cm behind each nipple, softer, mildly tender; no discrete mass |
| Laboratory | Testosterone, estradiol, LH, and FSH | Every 6 to 8 weeks after the exposure stops, until normal | Completed today | Testosterone 238 ng/dL (low, rising); estradiol 26 pg/mL; LH 2.4 and FSH 3.1 mIU/mL, now in range |
| Laboratory | Prolactin after the estrogen clears | Repeat once after a raised value | Completed today | 12.4 ng/mL, normal, down from 21.6; the rise was estrogen-related |
| Laboratory | Hemoglobin while testosterone is low | With each hormone check until normal | Completed today | 13.6 g/dL, back in range |
| Medication safety | Testosterone therapy | Only for persistent, symptomatic, confirmed testosterone deficiency | Not indicated | Not given while the axis recovers: it would suppress LH and FSH again and is not indicated for a transient, drug-induced low testosterone |
| Survey | PHQ-9 | Baseline, then at least monthly during acute treatment; every 2 to 4 weeks in continuation | Completed today | 12, down 20 percent from 15: partial response; bupropion added. Six weeks since the last score, two weeks beyond the monthly interval, because this review was timed to the hormone tests; no harm, as he had weekly therapy sessions and no suicidal thoughts |
| Survey | GAD-7 | With the PHQ-9 when anxiety symptoms were present at baseline | Completed today | 6, down from 8 |
| Survey | Suicide risk reassessment (C-SSRS Since Last Visit and PHQ-9 item 9) | Every visit during active treatment | Completed today | No suicidal thoughts, intent, plan, or behavior since the last visit; PHQ-9 item 9 scored 0. Protective factors unchanged; safety plan reviewed |
| Survey | Bipolar screen before starting an antidepressant | At the initial workup; repeat if hypomanic features emerge | Completed today | Still no history of elevated mood, reduced need for sleep, or racing thoughts |
| Medication safety | Antidepressant tolerability check two weeks after starting | 2 weeks after starting and after each dose change | Due | Nurse telephone check booked for two weeks from today |
| Self-management | Psychotherapy, sleep, running, and social contact | Every visit during active treatment | Completed today | Seven sessions; running about 25 km a week; early waking |
| Laboratory | Lithium, anticonvulsant, or antipsychotic monitoring (levels, metabolic tests, AIMS) | Only on those drugs | Not indicated | Not on any of these drugs |

## Goal progress

- Testosterone, LH, and FSH back in the reference range within six months of the last estrogen dose, without testosterone therapy. In progress; target 1953-08-04. **S**
- Breast tenderness gone and gynecomastia reduced; a surgical opinion offered if it persists and troubles him. In progress; target 1953-10-06. **S**
- Depression response (PHQ-9 down by at least 50 percent) by sixteen weeks, then remission (PHQ-9 below 5). In progress; target 1953-10-06. **S**
- Back to running about 40 km a week and changing at his club again. In progress; target 1953-10-06. **S**

## Medication changes

- Started: Bupropion extended-release 150 mg oral tablet, one tablet by mouth each morning **S**

## Guideline basis

- EAA clinical practice guidelines: gynecomastia evaluation and management (2019), European Academy of Andrology
- Testosterone Therapy in Men With Hypogonadism: An Endocrine Society Clinical Practice Guideline (2018), Endocrine Society
- VA/DoD Clinical Practice Guideline for the Management of Major Depressive Disorder (2022), United States Department of Veterans Affairs and Department of Defense
- VA/DoD Clinical Practice Guideline for Assessment and Management of Patients at Risk for Suicide (2024), United States Department of Veterans Affairs and Department of Defense
- CMID: Clinical Monitoring Intelligence Database, depression, bipolar, and mood disorders monograph (2026), Aether Forge

## Follow-up

- Nurse telephone check in two weeks; review in eight weeks with hormone tests and PHQ-9. **S**
- Next scheduled visit 1953-08-04: sixteen-week review of hormone recovery and depression treatment. **S**
